Liang Qu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Liang Qu has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Chunhui Wang
Biomedical Pioneering Innovation Center, Beijing Advanced Innovation Center for Genomics, Peking-Tsinghua Center for Life Sciences, Peking University Genome Editing Research Center, State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking University, Beijing, China
3 shared publicationsFei Gao
Frontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Fudan University, Shanghai, China
3 shared publicationsJie Yin
Frontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Fudan University, Shanghai, China
3 shared publicationsJing Li
Frontier Innovation Center, Department of Systems Biology for Medicine, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Fudan University, Shanghai, China
3 shared publicationsPengfei Yuan
EdiGene Inc., Life Science Park, Changping District, Beijing, China
3 shared publications- Wensheng Wei
Biomedical Pioneering Innovation Center, Peking-Tsinghua Center for Life Sciences, Peking University Genome Editing Research Center, State Key Laboratory of Gene Function and Modulation Research, School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing 102206, China
3 shared publications
Latest Publications
- Open Access
- 16 July 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (29)
IVT-free, chemically synthesized protein-encoding RNA oligonucleotides for rapid production of personalized cancer vaccines.
Personalized mRNA neoantigen vaccines demonstrate great potential in cancer therapy, but their customization typically requires more than three months, risking the loss of the optimal therapeutic window for patients. This delay is primarily due to the reliance of current mRNA vaccine production on plasmid fermentation and in vitro transcription (IVT), which involve multiple complex steps. Chemically synthesized RNA oligonucleotides, such as antisense oligonucleotides (ASOs), are produced sparing DNA templates or IVT, thus enabling rapid manufacturing. However, ASOs are limited in length, which precludes their ability to encode proteins. Here, we introduced a 39 nucleotides cap-independent translation enhancer (CITE) element termed BBV that can drive RNA translation. Furthermore, BBV was compatible with efficient rolling circle translation (RCT). We chemically synthesized RNA oligonucleotides containing BBV and gene of interest (GOI) with characteristic 5'-OH and 3'-P termini, which could undergo circularization by endogenous RtcB RNA ligases and efficiently encode proteins through RCT in mammalian cells. We designated these RNA oligonucleotides as Protein-Encoding RNA Oligonucleotides (PEOs). Notably, compared with IVT-produced RNAs, PEOs contained undetectable levels of proinflammatory double-stranded RNAs and exhibited minimal immunogenicity. We further demonstrated that PEO-OVA (encoding OVA antigens) significantly inhibited tumor growth comparable to mRNA vaccine. In an orthotopic glioma model, PEO vaccine also exhibited therapeutic benefits with checkpoint blockade therapy. This study establishes an IVT-free RNA vaccine platform that enables rapid, safe, and highly druggable manufacturing of personalized cancer vaccines, offering substantial potential for clinical application.
- 16 July 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (29)
Open AccessIVT-free, chemically synthesized protein-encoding RNA oligonucleotides for rapid production of personalized cancer vaccines.
Personalized mRNA neoantigen vaccines demonstrate great potential in cancer therapy, but their customization typically requires more than three months, risking the loss of the optimal therapeutic window for patients. This delay is primarily due to the reliance of current mRNA vaccine production on plasmid fermentation and in vitro transcription (IVT), which involve multiple complex steps. Chemically synthesized RNA oligonucleotides, such as antisense oligonucleotides (ASOs), are produced sparing DNA templates or IVT, thus enabling rapid manufacturing. However, ASOs are limited in length, which precludes their ability to encode proteins. Here, we introduced a 39 nucleotides cap-independent translation enhancer (CITE) element termed BBV that can drive RNA translation. Furthermore, BBV was compatible with efficient rolling circle translation (RCT). We chemically synthesized RNA oligonucleotides containing BBV and gene of interest (GOI) with characteristic 5'-OH and 3'-P termini, which could undergo circularization by endogenous RtcB RNA ligases and efficiently encode proteins through RCT in mammalian cells. We designated these RNA oligonucleotides as Protein-Encoding RNA Oligonucleotides (PEOs). Notably, compared with IVT-produced RNAs, PEOs contained undetectable levels of proinflammatory double-stranded RNAs and exhibited minimal immunogenicity. We further demonstrated that PEO-OVA (encoding OVA antigens) significantly inhibited tumor growth comparable to mRNA vaccine. In an orthotopic glioma model, PEO vaccine also exhibited therapeutic benefits with checkpoint blockade therapy. This study establishes an IVT-free RNA vaccine platform that enables rapid, safe, and highly druggable manufacturing of personalized cancer vaccines, offering substantial potential for clinical application.
- Open Access
- 29 June 2026
- Published by Springer Nature in Nature Biomedical Engineering
- p. 1-21
Engineered circular RNA compatible with complete nucleoside modification and rolling circle translation through a Cap-independent translation enhancer
Circular RNA (circRNA) exhibits extended stability and enhanced protein expression, and its translational efficiency and immunogenicity can be improved through nucleoside modification and rolling circle translation (RCT). However, it remains challenging to produce protein-encoding circRNA with modified nucleosides. Here we identified a cap-independent translation enhancer (CITE) element from black beetle virus, termed BBV, which could drive the translation of nucleoside-modified RNA and RCT of engineered circRNA. In addition, we developed a system to produce ‘scarless’ circRNA via in vitro transcription (IVT). The resulting circRNA vaccine outperformed m1ψ-mRNA vaccine in inhibiting tumour growth in mice. With nucleoside modification, circRNA exhibited reduced expression of pro-inflammatory cytokines. Further, nucleoside-modified circRNA encoding glucagon-like peptide-1 (GLP-1) peptides reduced blood glucose levels with efficacy comparable to that of commercial semaglutide, and ameliorated liver damage in obese mice. Moreover, nucleoside-modified circRNA encoding myelin oligodendrocyte glycoprotein (MOG35–55) peptides induced immune tolerance and alleviated disease progression in an experimental autoimmune encephalomyelitis (EAE) murine model. Collectively, we established a nucleoside-modified circRNA platform that facilitated efficient translation with minimal immunogenicity, expanding the application scenarios of circRNA beyond vaccines.
- 29 June 2026
- Published by Springer Nature in Nature Biomedical Engineering
- p. 1-21
Open AccessEngineered circular RNA compatible with complete nucleoside modification and rolling circle translation through a Cap-independent translation enhancer
Circular RNA (circRNA) exhibits extended stability and enhanced protein expression, and its translational efficiency and immunogenicity can be improved through nucleoside modification and rolling circle translation (RCT). However, it remains challenging to produce protein-encoding circRNA with modified nucleosides. Here we identified a cap-independent translation enhancer (CITE) element from black beetle virus, termed BBV, which could drive the translation of nucleoside-modified RNA and RCT of engineered circRNA. In addition, we developed a system to produce ‘scarless’ circRNA via in vitro transcription (IVT). The resulting circRNA vaccine outperformed m1ψ-mRNA vaccine in inhibiting tumour growth in mice. With nucleoside modification, circRNA exhibited reduced expression of pro-inflammatory cytokines. Further, nucleoside-modified circRNA encoding glucagon-like peptide-1 (GLP-1) peptides reduced blood glucose levels with efficacy comparable to that of commercial semaglutide, and ameliorated liver damage in obese mice. Moreover, nucleoside-modified circRNA encoding myelin oligodendrocyte glycoprotein (MOG35–55) peptides induced immune tolerance and alleviated disease progression in an experimental autoimmune encephalomyelitis (EAE) murine model. Collectively, we established a nucleoside-modified circRNA platform that facilitated efficient translation with minimal immunogenicity, expanding the application scenarios of circRNA beyond vaccines.
- Open Access
- 24 July 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (8) , 102250
Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting
- 24 July 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (8) , 102250
Open AccessSynergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting
- Open Access
Synergically enhanced anti-tumor immunity of in vivo CAR by circRNA vaccine boosting
Chimeric Antigen Receptor (CAR) T cell therapy has shown promise in treating hematologic malignancies. However, it is limited to individualized cell therapy and faces challenges, including high costs, extended preparation time, and limited efficacy against solid tumors. Here, we generated circular RNAs (circRNAs) encoding Chimeric Antigen Receptor (CAR) transmembrane proteins, referred to as circRNA CAR , which mediated remarkable tumor killing in both T cells and macrophages. In addition, macrophages exhibited efficient phagocytosis of tumor cells and pro-inflammatory polarization induced by circRNA CAR in vitro . We demonstrated that circRNA CAR , delivered with immunocyte-tropic lipid nanoparticles (LNPs), significantly inhibited tumor growth, improved survival rates and induced a pro-inflammatory tumor microenvironment in mice. Importantly, the combination of circRNA Anti-HER2-CAR and circRNA-based cancer vaccines encoding the corresponding transmembrane HER2 antigen, termed circRNA HER2 , exhibited synergistically enhanced anti-tumor activity. This proof-of-concept study demonstrated that the combination of circRNA-based in vivo CAR and vaccines, termed in vivo CAR-VAC, holds the potential to become an upgraded off-the-shelf immunotherapy.
Open AccessSynergically enhanced anti-tumor immunity of in vivo CAR by circRNA vaccine boosting
Chimeric Antigen Receptor (CAR) T cell therapy has shown promise in treating hematologic malignancies. However, it is limited to individualized cell therapy and faces challenges, including high costs, extended preparation time, and limited efficacy against solid tumors. Here, we generated circular RNAs (circRNAs) encoding Chimeric Antigen Receptor (CAR) transmembrane proteins, referred to as circRNA CAR , which mediated remarkable tumor killing in both T cells and macrophages. In addition, macrophages exhibited efficient phagocytosis of tumor cells and pro-inflammatory polarization induced by circRNA CAR in vitro . We demonstrated that circRNA CAR , delivered with immunocyte-tropic lipid nanoparticles (LNPs), significantly inhibited tumor growth, improved survival rates and induced a pro-inflammatory tumor microenvironment in mice. Importantly, the combination of circRNA Anti-HER2-CAR and circRNA-based cancer vaccines encoding the corresponding transmembrane HER2 antigen, termed circRNA HER2 , exhibited synergistically enhanced anti-tumor activity. This proof-of-concept study demonstrated that the combination of circRNA-based in vivo CAR and vaccines, termed in vivo CAR-VAC, holds the potential to become an upgraded off-the-shelf immunotherapy.
- Top Cited Papers
- 10 February 2022
- Published by Springer Nature in Nature Biotechnology
- Vol. 40 (6) , 946-955
Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo
Current methods for programmed RNA editing using endogenous ADAR enzymes and engineered ADAR-recruiting RNAs (arRNAs) suffer from low efficiency and bystander off-target editing. Here, we describe LEAPER 2.0, an updated version of LEAPER that uses covalently closed circular arRNAs, termed circ-arRNAs. We demonstrate on average ~3.1-fold higher editing efficiency than their linear counterparts when expressed in cells or delivered as in vitro-transcribed circular RNA oligonucleotides. To lower off-target editing we deleted pairings of uridines with off-target adenosines, which almost completely eliminated bystander off-target adenosine editing. Engineered circ-arRNAs enhanced the efficiency and fidelity of editing endogenous CTNNB1 and mutant TP53 transcripts in cell culture. Delivery of circ-arRNAs using adeno-associated virus in a mouse model of Hurler syndrome corrected the pathogenic point mutation and restored α-L-iduronidase catalytic activity, lowering glycosaminoglycan accumulation in the liver. LEAPER 2.0 provides a new design of arRNA that enables more precise, efficient RNA editing with broad applicability for therapy and basic research.
- 10 February 2022
- Published by Springer Nature in Nature Biotechnology
- Vol. 40 (6) , 946-955
Top Cited PapersEngineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo
Current methods for programmed RNA editing using endogenous ADAR enzymes and engineered ADAR-recruiting RNAs (arRNAs) suffer from low efficiency and bystander off-target editing. Here, we describe LEAPER 2.0, an updated version of LEAPER that uses covalently closed circular arRNAs, termed circ-arRNAs. We demonstrate on average ~3.1-fold higher editing efficiency than their linear counterparts when expressed in cells or delivered as in vitro-transcribed circular RNA oligonucleotides. To lower off-target editing we deleted pairings of uridines with off-target adenosines, which almost completely eliminated bystander off-target adenosine editing. Engineered circ-arRNAs enhanced the efficiency and fidelity of editing endogenous CTNNB1 and mutant TP53 transcripts in cell culture. Delivery of circ-arRNAs using adeno-associated virus in a mouse model of Hurler syndrome corrected the pathogenic point mutation and restored α-L-iduronidase catalytic activity, lowering glycosaminoglycan accumulation in the liver. LEAPER 2.0 provides a new design of arRNA that enables more precise, efficient RNA editing with broad applicability for therapy and basic research.
- 25 September 2019
- Published by Springer Nature in Nature Biotechnology
- Vol. 37 (11) , 1380
Author Correction: Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 25 September 2019
- Published by Springer Nature in Nature Biotechnology
- Vol. 37 (11) , 1380
Author Correction: Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 15 July 2019
- Published by Springer Nature in Nature Biotechnology
- Vol. 37 (9) , 1059-1069
Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs
Current tools for targeted RNA editing rely on the delivery of exogenous proteins or chemically modified guide RNAs, which may lead to aberrant effector activity, delivery barrier or immunogenicity. Here, we present an approach, called leveraging endogenous ADAR for programmable editing of RNA (LEAPER), that employs short engineered ADAR-recruiting RNAs (arRNAs) to recruit native ADAR1 or ADAR2 enzymes to change a specific adenosine to inosine. We show that arRNA, delivered by a plasmid or viral vector or as a synthetic oligonucleotide, achieves editing efficiencies of up to 80%. LEAPER is highly specific, with rare global off-targets and limited editing of non-target adenosines in the target region. It is active in a broad spectrum of cell types, including multiple human primary cell types, and can restore α-L-iduronidase catalytic activity in Hurler syndrome patient-derived primary fibroblasts without evoking innate immune responses. As a single-molecule system, LEAPER enables precise, efficient RNA editing with broad applicability for therapy and basic research.
- 15 July 2019
- Published by Springer Nature in Nature Biotechnology
- Vol. 37 (9) , 1059-1069
Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs
Current tools for targeted RNA editing rely on the delivery of exogenous proteins or chemically modified guide RNAs, which may lead to aberrant effector activity, delivery barrier or immunogenicity. Here, we present an approach, called leveraging endogenous ADAR for programmable editing of RNA (LEAPER), that employs short engineered ADAR-recruiting RNAs (arRNAs) to recruit native ADAR1 or ADAR2 enzymes to change a specific adenosine to inosine. We show that arRNA, delivered by a plasmid or viral vector or as a synthetic oligonucleotide, achieves editing efficiencies of up to 80%. LEAPER is highly specific, with rare global off-targets and limited editing of non-target adenosines in the target region. It is active in a broad spectrum of cell types, including multiple human primary cell types, and can restore α-L-iduronidase catalytic activity in Hurler syndrome patient-derived primary fibroblasts without evoking innate immune responses. As a single-molecule system, LEAPER enables precise, efficient RNA editing with broad applicability for therapy and basic research.
- 1 October 2015
- Vol. 37 (10) , 974-82
The molecular mechanism of CRISPR/Cas9 system and its application in gene therapy of human diseases.
CRISPR/Cas system is an adaptive immune system that confers resistance to exogenous virus or plasmid in bacteria and archaea. In recent years, the booming CRISPR/Cas9 genome editing technology modified from type2 CRISPR/Cas adaptive immune system has been widely applied to various research fields of life science and led to revolutionary changes. In this review, we summarize the origin and development of CRISPR/Cas9 genome editing technology as well as its applications in life science research. We focus on the latest application of this system in gene therapy of human diseases and the associated side/off-target effects, which may provide references for researchers in related areas.
- 1 October 2015
- Vol. 37 (10) , 974-82
The molecular mechanism of CRISPR/Cas9 system and its application in gene therapy of human diseases.
CRISPR/Cas system is an adaptive immune system that confers resistance to exogenous virus or plasmid in bacteria and archaea. In recent years, the booming CRISPR/Cas9 genome editing technology modified from type2 CRISPR/Cas adaptive immune system has been widely applied to various research fields of life science and led to revolutionary changes. In this review, we summarize the origin and development of CRISPR/Cas9 genome editing technology as well as its applications in life science research. We focus on the latest application of this system in gene therapy of human diseases and the associated side/off-target effects, which may provide references for researchers in related areas.
- 1 June 2015
- Published by Elsevier in Antiviral Research
- Vol. 118, 110-117
Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication
- 1 June 2015
- Published by Elsevier in Antiviral Research
- Vol. 118, 110-117
Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication